Debiopharm International SA - O-STA

Monday, Dec 23, 2024

02.03.2023 09:00
Debiopharm extends their DNA repair footprint with new oncology pipeline entry
12.01.2023 09:00
DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
13.09.2022 15:42
Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
09.05.2022 11:24
Series A financing round lays foundation for international growth of digital cancer therapeutics Mika
01.02.2022 09:00
Debiopharm and Aspen partner to launch prostate cancer drug Trelstar® in South Africa
16.12.2021 09:00
Debiopharm further explores the potential of its potent, highly selective WEE1 inhibitor Debio 0123 in phase 1 chancer study
19.10.2021 09:00
Carb-x funds the 3rd round of Debiopharm's targeted antibiotic program to combat resistent n. gonorrhoeae infections
07.10.2021 09:00
DEBIOPHARM & DEXA MEDICA LAUNCH TRIPTORELIN COLLABORATION TO BRING NEW HOPE TO WOMEN WITH ENDOMETRIOSIS
04.10.2021 09:00
Debiopharm encourages breakthrough cancer research in Japan through its competitive JCA Mauvernay Award